ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Warszawa, Mazowieckie

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Non-Hodgkin Lymphoma
Lymphoid Leukemia
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Warszawa, Mazowieckie, POL:

A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas....

Enrolling
Lymphoma, T-Cell
Diffuse Large B Cell Lymphoma
Drug: CPI-0209

Phase 1, Phase 2

Constellation Pharmaceuticals

Warsaw, Poland and 59 other locations

TrAVeRse is a multicentre, open-label, Phase II study of AVR in treatment naïve MCL participants. The primary objective will be to assess the rate of...

Active, not recruiting
Mantle Cell Lymphoma (MCL)
Drug: Venetoclax
Drug: Rituximab

Phase 2

AstraZeneca
AstraZeneca

Warszawa, Poland and 28 other locations

treatment of advanced classical Hodgkin lymphoma(HL)...

Active, not recruiting
Hodgkin Lymphoma
Drug: vinblastine
Drug: brentuximab vedotin

Phase 3

Takeda
Takeda

Warszawa, Poland and 215 other locations

The purpose of this study is to assess the antitumor efficacy of single-agent brentuximab vedotin 1.8 mg/kg administered intravenously (IV) every 3 w...

Active, not recruiting
Lymphoma
Drug: Brentuximab vedotin

Phase 4

Takeda
Takeda

Warszawa, Poland and 39 other locations

to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma...

Enrolling
Lymphoma, Follicular
Drug: Golcadomide
Drug: Doxorubicin

Phase 2

Celgene
Celgene

Warszawa, Mazowieckie, Poland and 64 other locations

comprise 2 cohorts to assess safety and efficacy of emavusertib in combination with ibrutinib in patients with primary central nervous system lymphoma...

Enrolling
Refractory Primary Central Nervous System Lymphoma
Relapsed Primary Central Nervous System Lymphoma
Drug: ibrutinib
Drug: Emavusertib

Phase 1, Phase 2

Curis

Warsaw, Poland and 36 other locations

The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemoth...

Enrolling
Relapsed Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Drug: Gemcitabine
Drug: Rituximab

Phase 3

ADC Therapeutics

Warszawa, Poland and 143 other locations

The purpose of this trial is to measure the following in participants with relapsed and/or refractory B-cell lymphoma who receive epcoritama...

Active, not recruiting
Small Lymphocytic Lymphoma (SLL)
Marginal Zone Lymphoma (MZL)
Biological: Epcoritamab

Phase 1, Phase 2

Genmab
Genmab

Warszawa, Poland and 84 other locations

This study evaluates the addition of nivolumab to gemcitabine, oxaliplatin plus rituximab in case of B-cell lymphoma...

Active, not recruiting
Lymphoma, Non-Hodgkin
Device: Oxaliplatin
Drug: Rituximab

Phase 2, Phase 3

Universität des Saarlandes

Warsaw, Poland and 76 other locations

A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma...

Enrolling
Diffuse Large B-cell Lymphoma
Drug: Selinexor

Phase 2

Karyopharm Therapeutics
Karyopharm Therapeutics

Warszawa, Poland and 175 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems